Last reviewed · How we verify
SB659032
At a glance
| Generic name | SB659032 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease (PHASE2)
- Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (PHASE1)
- An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks (PHASE2)
- Effect Of Rilapladib (SB-659032) On Platelet Aggregation (PHASE1)
- A Study to Assess the Effect of SB 659032 on Platelet Function (PHASE1)
- SB-659032 Platelet Aggregation Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB659032 CI brief — competitive landscape report
- SB659032 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI